CYFRA21-1对早期非小细胞肺癌诊断价值的Meta分析  

Meta-analysis on the diagnostic value of CYFRA21-1 in early non-small cell lung cancer

作　　者：刘延峰[1] 杨拴盈[1] 尚文丽[1] 张薇[1] 霍淑芬[1] 卜丽娜[1] 戎彪学[1] 南岩东[1] 田应选[1] 

机构地区：[1]西安交通大学医学院第二附属医院呼吸内科,陕西西安710004

出　　处：《西安交通大学学报（医学版）》2011年第1期34-37,共4页Journal of Xi’an Jiaotong University（Medical Sciences）

摘　　要：目的评价CYFRA21-1对早期非小细胞肺癌诊断的价值。方法收集已公开发表的有关CYFRA21-1对早期非小细胞肺癌诊断价值的文献,按Meta分析的要求对检索到的原始研究的质量进行评估,对符合条件的所有研究结果进行Meta分析。结果共纳入9篇文献,其中中文文献6篇,英文文献3篇,样本量为670例,其中经病理学确诊的Ⅰ、Ⅱ期及可手术治疗的NSCLC为276例,异质性检验显示纳入研究齐性较好,通过确定模型的汇总计算得出汇总敏感度为41%(35%～46%),汇总特异度为94%(91%～96%),汇总阳性预测值为5.65(3.45～9.27),汇总阴性预测值为0.64(0.54～0.76),合并受试者工作特征曲线(SROC)的曲线下面积为0.85。结论 CYFRA21-1对早期非小细胞肺癌有一定的诊断价值,可作为较重要的参考指标之一,但需要更多高质量、大样本、多中心的研究加以验证。Objective To evaluate the diagnostic value of CYFRA21-1 in early non-small cell lung cancer（NSCLC）.Methods All published clinical studies that evaluated the diagnostic value of CYFRA21-1 in non-small cell lung cancer were reviewed.The quality of the retrieved original studies was evaluated according to the requirements of meta-analysis.Meta-analysis was used in all eligible studies.Results Nine studies including six in Chinese and three in English were collected.The sample size was 670 cases,of which 276 cases confirmed pathologically were in stage Ⅰ-Ⅱ and resectable.Heterogeneity test showed that the homogeneity of the studies was good.Deterministic model was used to analyze the data.The value of the weighted sensitivity was 41%（35%-46%）,the specificity was 94%（91%-96%）,the positive likelihood ratio was 5.65（3.45-9.27）,the negative likelihood ratio was 0.64（0.54-0.76）,and the SROC area under the curve（AUC） was 0.85.Conclusion CYFRA21-1 can be regarded as a valuable marker in early NSCLC diagnosis;however,but more high-quality,large-sized and multi-center studies are still required to evaluate its clinical value.

关 键 词：CYFRA21-1 非小细胞肺癌 META分析 

分 类 号：R734.1[医药卫生—肿瘤]